PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32384236-4 2020 We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -). Doxorubicin 32-35 integrin subunit alpha V Homo sapiens 130-150 18710273-0 2008 Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Doxorubicin 35-46 integrin subunit alpha V Homo sapiens 85-86 18578486-0 2008 In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3. Doxorubicin 35-46 integrin subunit alpha V Homo sapiens 111-131 34977030-3 2021 Using a Cal27 tongue squamous cell carcinoma model, we have previously demonstrated that de novo expression of integrin alphaVbeta3 confers resistance to several anticancer drugs (cisplatin, mitomycin C and doxorubicin) through a mechanism involving downregulation of active Src, increased cell migration and invasion. Doxorubicin 207-218 integrin subunit alpha V Homo sapiens 111-131 32384236-4 2020 We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -). Doxorubicin 32-35 integrin subunit alpha V Homo sapiens 201-221 27533248-4 2016 In the presence of the RGD motif, the Dox/P45 nanospheres could specifically target A549 cells, which have high integrin alphavbeta3 expression. Doxorubicin 38-41 integrin subunit alpha V Homo sapiens 112-132 24757954-1 2014 A novel drug delivery system c(RGDyK)-modified Fe3O4 nanoparticles with high DOX load (R-DMP), which combines magnetic targeting, integrin alpha(v)beta3 targeting and high drug loading properties, was developed by chemical coupling both doxorubicin and peptide c(RGDyK) on the synthetic dual function magnetic nanoparticles (DMP) using a multi-hand cross-linker poly-L-glutamic acid. Doxorubicin 77-80 integrin subunit alpha V Homo sapiens 130-152 24757954-1 2014 A novel drug delivery system c(RGDyK)-modified Fe3O4 nanoparticles with high DOX load (R-DMP), which combines magnetic targeting, integrin alpha(v)beta3 targeting and high drug loading properties, was developed by chemical coupling both doxorubicin and peptide c(RGDyK) on the synthetic dual function magnetic nanoparticles (DMP) using a multi-hand cross-linker poly-L-glutamic acid. Doxorubicin 237-248 integrin subunit alpha V Homo sapiens 130-152 24757954-4 2014 Compare with those of doxorubicin coupled DMP without peptide c(RGDyK) modification, D-DMP shows enhanced uptake by integrin alpha(v)beta3 targeting expressing tumor cells and displays stronger cancer cell cytotoxicity. Doxorubicin 22-33 integrin subunit alpha V Homo sapiens 116-138 23623323-0 2013 The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells. Doxorubicin 57-68 integrin subunit alpha V Homo sapiens 72-92 23623323-7 2013 The prepared large size RGD-PEG-LP that targets the TECs via interacting with Integrin alphavbeta3, is a potentially effective and alternate therapeutic strategy for the treatment of DOX resistant tumor cells by utilizing DOX, in cases where Doxil is ineffective. Doxorubicin 183-186 integrin subunit alpha V Homo sapiens 78-98 23623323-7 2013 The prepared large size RGD-PEG-LP that targets the TECs via interacting with Integrin alphavbeta3, is a potentially effective and alternate therapeutic strategy for the treatment of DOX resistant tumor cells by utilizing DOX, in cases where Doxil is ineffective. Doxorubicin 222-225 integrin subunit alpha V Homo sapiens 78-98 24513318-3 2014 Herein, a pH-responsive charge-reversal polyelectrolyte and integrin alphaVbeta3 mono-antibody functionalized graphene oxide (GO) complex is constituted as a nanocarrier for targeted delivery and controlled release of DOX into cancer cells. Doxorubicin 218-221 integrin subunit alpha V Homo sapiens 60-80